Versant Venture Capital IV, L.P.
CIK 0001456590 Name as filed on the most recent filing
Filed as Versant Venture Capital IV, L.P. (6)
19 transaction lines · from 6 filings · filed 2011-11-17 to 2024-08-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Tempest Therapeutics, Inc. 1 filings
- ISSUER Oyster Point Pharma, Inc. 2 filings
- ISSUER Crispr Therapeutics AG 2 filings
- ISSUER Clovis Oncology, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2024-08-12 |
Tempest Therapeutics, Inc. TPST |
S, Open-market sale | 387,999 disposed | 1.10 | 426,992.90 | Form 4, filing 0000950170-24-095675 | |
| 2024-08-08 |
Tempest Therapeutics, Inc. TPST |
S, Open-market sale | 400,000 disposed | 1.35 | 540,040.00 | Form 4, filing 0000950170-24-095675 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 303,614 disposed | 14.63 | 4,442,692.58 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 242,943 disposed | 15.09 | 3,666,957.35 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 1,912 disposed | 14.63 | 27,977.72 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 1,531 disposed | 15.09 | 23,108.76 | Form 4, filing 0000899243-21-040777 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 437,500 acquired | 16.00 | 7,000,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 125,000 acquired | 16.00 | 2,000,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 27,500 acquired | 16.00 | 440,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2018-04-23 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 89,628 disposed | 50.66 | 4,540,554.48 | Form 4, filing 0000899243-18-010684 | |
| 2018-04-23 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 6,821 disposed | 50.66 | 345,551.86 | Form 4, filing 0000899243-18-010684 | |
| 2018-04-23 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 2,915 disposed | 51.00 | 148,665.00 | Form 4, filing 0000899243-18-010684 | |
| 2018-04-23 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 2,630 disposed | 51.00 | 134,130.00 | Form 4, filing 0000899243-18-010684 | |
| 2016-10-24 |
Crispr Therapeutics AG CRSP |
P, Open-market purchase | 95,596 acquired | 14.00 | 1,338,344.00 | Form 4, filing 0001104659-16-163806 | |
| 2016-10-24 |
Crispr Therapeutics AG CRSP |
P, Open-market purchase | 60,219 acquired | 14.00 | 843,066.00 | Form 4, filing 0001104659-16-163806 | |
| 2016-10-24 |
Crispr Therapeutics AG CRSP |
P, Open-market purchase | 4,583 acquired | 14.00 | 64,162.00 | Form 4, filing 0001104659-16-163806 | |
| 2016-10-24 |
Crispr Therapeutics AG CRSP |
P, Open-market purchase | 602 acquired | 14.00 | 8,428.00 | Form 4, filing 0001104659-16-163806 | |
| 2011-11-16 |
Clovis Oncology, Inc. CLVS |
P, Open-market purchase | 661,323 acquired | Not reported | Not priced | Form 4, filing 0001104659-11-064948 | |
| 2011-11-16 |
Clovis Oncology, Inc. CLVS |
P, Open-market purchase | 4,165 acquired | Not reported | Not priced | Form 4, filing 0001104659-11-064948 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Versant Venture Capital IV, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001456590
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6